iRadimed (NASDAQ:IRMD) Releases FY 2026 Earnings Guidance

iRadimed (NASDAQ:IRMD) issued an update on its FY 2026 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of 2.060-2.210 for the period, compared to the consensus estimate of 2.050. The company issued revenue guidance of $91.0 million-$96.0 million, compared to the consensus revenue estimate of $92.4 million. iRadimed also updated its Q2 2026 guidance to 0.440-0.480 EPS.

iRadimed Stock Performance

Shares of NASDAQ IRMD traded up $3.71 during mid-day trading on Friday, reaching $87.15. 346,336 shares of the company’s stock were exchanged, compared to its average volume of 103,465. The firm has a market capitalization of $1.11 billion, a price-to-earnings ratio of 49.80 and a beta of 0.91. iRadimed has a 52-week low of $50.31 and a 52-week high of $107.90. The company’s 50-day moving average is $96.69 and its 200-day moving average is $93.87.

iRadimed (NASDAQ:IRMD) last released its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $0.54 earnings per share for the quarter, topping analysts’ consensus estimates of $0.49 by $0.05. The business had revenue of $22.69 million during the quarter, compared to analysts’ expectations of $21.60 million. iRadimed had a return on equity of 23.83% and a net margin of 26.82%.iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. As a group, equities analysts predict that iRadimed will post 1.94 earnings per share for the current fiscal year.

iRadimed Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 29th. Investors of record on Friday, May 15th will be paid a dividend of $0.20 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $0.80 annualized dividend and a yield of 0.9%. iRadimed’s dividend payout ratio is presently 45.71%.

Wall Street Analysts Forecast Growth

IRMD has been the topic of several research reports. Lake Street Capital reissued a “buy” rating and set a $120.00 target price on shares of iRadimed in a research note on Wednesday, February 11th. Roth Mkm reissued a “buy” rating and set a $120.00 target price on shares of iRadimed in a research note on Tuesday, February 10th. Finally, Freedom Capital raised iRadimed to a “strong-buy” rating in a research note on Thursday, April 2nd. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, iRadimed presently has a consensus rating of “Buy” and a consensus target price of $120.00.

Insider Transactions at iRadimed

In other iRadimed news, CEO Roger E. Susi sold 3,750 shares of the stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $89.16, for a total value of $334,350.00. Following the sale, the chief executive officer owned 2,198,750 shares of the company’s stock, valued at $196,040,550. This trade represents a 0.17% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 48,750 shares of company stock valued at $4,708,950. 36.80% of the stock is owned by company insiders.

Key Stories Impacting iRadimed

Here are the key news stories impacting iRadimed this week:

• Positive Sentiment: Q1 earnings and revenue beat consensus: iRadimed reported non?GAAP EPS of $0.49 (GAAP $0.45) and revenue of ~$22.0M, both above expectations, with year?over?year EPS and revenue growth — a primary driver of the intraday rally. iRadimed (IRMD) Beats Q1 Earnings and Revenue Estimates
• Positive Sentiment: Record GAAP and improved margins: management highlighted record GAAP diluted EPS and improved net margin/ROE metrics, signaling operating leverage and pricing/volume strength. IRADIMED Reports First Quarter 2026 Financial Results
• Positive Sentiment: Dividend increase maintained: the company announced a regular quarterly cash dividend of $0.20 (up from $0.17), which supports income-oriented investors and signals confidence in cash flow. IRADIMED Reports First Quarter 2026 Financial Results
• Neutral Sentiment: Full?year guidance reaffirmed and nudged slightly above consensus: FY2026 EPS guidance was set to $2.06–$2.21 (consensus ~2.05), and revenue guidance roughly $91–96M (consensus ~$92.4M) — supportive but not a major beat. IRADIMED Reports First Quarter 2026 Financial Results
• Neutral Sentiment: CEO insider sale disclosed: CEO Roger Susi sold 3,750 shares under a pre?arranged Rule 10b5?1 plan — a small, orderly sale that management says was planned, so likely neutral for most investors. Insider Selling: iRadimed CEO Sells Shares
• Negative Sentiment: Q2 revenue and mid?point EPS guidance slightly cautious vs. street: Q2 revenue guidance of $20.0–$21.0M is modestly below consensus (~$21.1M) and Q2 EPS guidance (0.44–0.48) straddles the street estimate — this introduces short?term execution risk that could temper gains. IRADIMED Reports First Quarter 2026 Financial Results

Institutional Investors Weigh In On iRadimed

Hedge funds have recently bought and sold shares of the stock. PharVision Advisers LLC acquired a new stake in iRadimed in the 3rd quarter valued at about $257,000. Boothbay Fund Management LLC acquired a new stake in iRadimed in the 3rd quarter valued at about $279,000. Creative Planning acquired a new stake in iRadimed in the 3rd quarter valued at about $315,000. Osaic Holdings Inc. raised its position in iRadimed by 766.6% in the 2nd quarter. Osaic Holdings Inc. now owns 3,813 shares of the medical equipment provider’s stock valued at $228,000 after purchasing an additional 3,373 shares in the last quarter. Finally, Brevan Howard Capital Management LP acquired a new stake in iRadimed in the 2nd quarter valued at about $260,000. Institutional investors and hedge funds own 92.34% of the company’s stock.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.